A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration

Trial Profile

A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms VIPP
  • Sponsors Roche
  • Most Recent Events

    • 22 Nov 2017 Primary endpoint (Time to graft loss up to 84 months) has not been met, according to long-term results published in the Transplantation Journal.
    • 22 Nov 2017 Long-term results of this study (7 years follow-up), published in the Transplantation Journal.
    • 31 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top